Biocon Biologics receives U.S. FDA approval for Jobevne

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable biologics.

The U.S. Food and Drug Administration (U.S. FDA) has approved Biocon Biologics’ Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use.

JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor, says a company communique issued on Thursday (April 10, 2025) morning.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said, “The U.S. FDA approval of JOBEVNE (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics.”